Tsung-Yan Chen

Tsung-Yan Chen

Auto-generated profile, based on publicly available information

Tsung-Yan Chen

Cardiovascular center, National Taiwan University Hospital, Hsinchu Branch, Hsinchu, Taiwan

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
MLMin-Tsun Liao
Min-Tsun Liao
CLCheng-Pin Lee
Cheng-Pin Lee
TLTing-Tse Lin
Ting-Tse Lin
CJChien-Boon Jong
Chien-Boon Jong
TCTsung-Yan Chen
Tsung-Yan Chen
CWChih-Cheng Wu
Chih-Cheng Wu

1 April 2018 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
MHMu-Yang Hsieh
Mu-Yang Hsieh
LLLin Lin
Lin Lin
TCTsung-Yan Chen
Tsung-Yan Chen
DCDao-Ming Chen
Dao-Ming Chen
MLMing-Hsien Lee
Ming-Hsien Lee
KHKuan-Yu Hung
Kuan-Yu Hung

26 October 2016 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
CWChih-Cheng Wu
Chih-Cheng Wu
TCTsung-Yan Chen
Tsung-Yan Chen
MHMu-Yang Hsieh
Mu-Yang Hsieh
LLLin Lin
Lin Lin
WYwei chung Yang
wei chung Yang
DTDer-Cherng Tarng
Der-Cherng Tarng
Background and objectives: Inflammation is relevant in restenosis of atherosclerotic vascular diseases, but its role in dialysis arteriovenous fistula remains unknown. In animal studies, upregulation of monocyte chemoattractant protein-1 has been shown in venous segments of arteriovenous fistula. We, therefore, aimed to investigate serial changes in circulating monocyte chemoattractant protein-1 after percutaneous transluminal angioplasty of dialysis arteriovenous fistulas and its relation to restenosis. Design, setting, participants, & measurements: Fifty-nine patients with dysfunctional arteriovenous fistulas that were referred for percutaneous transluminal angioplasty were enrolled prospectively between January of 2010 and July of 2012. Three of them were excluded due to percutaneous transluminal angioplasty failure or acute infection. Blood was sampled from arteriovenous fistulas at baseline, 2 days, 2 weeks, and 3 months after percutaneous transluminal angioplasty. Clinical follow-up was continued monthly for 3 months. Angiographic follow-up was arranged at the end of 3 months. Seventeen patients without significant stenosis were enrolled as the control group. Results: Fifty-six patients completed clinical follow-up. Significant increases in monocyte chemoattractant protein-1 were observed at 2 days and 2 weeks (both P<0.001) after percutaneous transluminal angioplasty. Twenty-three (41%) patients had symptomatic restenosis. The restenosis group had a higher percentage change in monocyte chemoattractant protein-1 levels at 2 days (median =47%; interquartile range, 27%–65% versus median =17%; interquartile range, 10%–25%; P<0.001) after percutaneous transluminal angioplasty compared with the patent group. Fifty-two patients completed angiographic follow-up. A positive correlation between relative luminal loss and monocyte chemoattractant protein-1 increase at 2 days after percutaneous transluminal angioplasty was found (r=0.53; P25% postangioplasty increase of monocyte chemoattractant protein-1 was significantly associated with restenosis after percutaneous transluminal angioplasty (hazard ratio, 5.36; 95% confidence interval, 1.81 to 15.8). Conclusions: Circulating monocyte chemoattractant protein-1 levels were elevated 2 days and 2 weeks after percutaneous transluminal angioplasty. Early postangioplasty increase of monocyte chemoattractant protein-1 level was associated with restenosis of arteriovenous fistulas.

17 January 2017 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
MHMu-Yang Hsieh
Mu-Yang Hsieh
TCTsung-Yan Chen
Tsung-Yan Chen
LLLin Lin
Lin Lin
SCShao-Yuan Chuang
Shao-Yuan Chuang
SLShing-Jong Lin
Shing-Jong Lin
CWChih-Cheng Wu
Chih-Cheng Wu
Background. Hemodialysis (HD) patients have an increased risk of thrombosis. Endothelial progenitor cells (EPCs), which function in vascular repair, are deficient in HD patients. Nonetheless, the relationship between EPC deficiency and thrombosis in HD patients is unknown. Methods. From January 2010 to December 2012, circulating levels of EPCs that were positive for CD34 and kinase insert domain receptor (KDR) were measured in 269 HD patients. Patients received prospective follow-ups at 6-month intervals until May 2015. The primary outcome was the composite of HD access thrombosis and systemic vascular thrombosis. Results. There were 141 thrombotic events, 50 systemic vascular thrombotic events and 116 HD access thrombotic events. We found significantly negative associations between CD34+ KDR+ tertile and overall thrombotic events (low: 61%; middle: 56%; high: 40%; P = 0.02), systemic vascular thrombotic events (low: 27%; middle: 18%; high: 10%; P = 0.03) and HD access thrombotic events (low: 52%; middle: 46%; high: 36%; P = 0.02). Univariate analysis indicated that systemic vascular thrombotic events were positively associated with age, diabetes, dyslipidemia, vascular disease history, urea clearance, albumin and C-reactive protein (CRP), and negatively associated with CD34+ KDR+ cell count. HD access thrombosis was positively associated with vascular disease history and CRP, and negatively associated with CD34+ KDR+ cell count. Multivariate analysis indicated that a low CD34+ KDR+ cell count was an independent risk factor for both types of thrombosis. Conclusions. Our study of a population of HD patients showed that a low level of circulating EPCs is associated with thrombosis.

31 July 2018 in CardioVascular and Interventional Radiology
Verified
Journal Article
Closed access
PDF file
TCTsung-Yan Chen
Tsung-Yan Chen
LLLin Lin
Lin Lin
MHMu-Yang Hsieh
Mu-Yang Hsieh
CCChiu-Hui Chen
Chiu-Hui Chen
MCMeng-Kan Chen
Meng-Kan Chen
CWChih-Cheng Wu
Chih-Cheng Wu

27 October 2016 in American Journal of Nephrology
Verified
Journal Article
Closed access
PDF file
TCTsung-Yan Chen
Tsung-Yan Chen
TLTing-Tse Lin
Ting-Tse Lin
MHMu-Yang Hsieh
Mu-Yang Hsieh
LLLin Lin
Lin Lin
WYwei chung Yang
wei chung Yang
CWChih-Cheng Wu
Chih-Cheng Wu
Background: Arteriovenous fistula (AVF) thrombosis is a relevant cause of morbidity in hemodialysis (HD) patients. The number of circulating endothelial progenitor cells (EPCs) has been identified as a surrogate marker for vascular repair and health. Deficiency of EPCs has been demonstrated in dialysis patients to be associated with vascular events. Nonetheless, their role in thrombosis of AVFs remains unknown. Methods: From January 2010 to May 2013, 147 HD patients with dysfunctional AVFs were enrolled. Surface makers including CD34, KDR and CD133 were used in combination to determine the number of circulating EPCs. All participants were prospectively followed at 6-month interval until December 2015. The primary outcome was thrombosis of dialysis AVFs. Results: The median follow-up was 47 months, within which 42 patients experienced at least one episode of AVF thrombosis. Patients with AVF thrombosis had lower CD34+KDR+ cell counts compared with patients without thrombosis (median 5 vs. 13 per 150,000 mononuclear cells, p < 0.001). Kaplan-Meier analysis demonstrated an inverse relationship between CD34+KDR+ cell count tertiles and thrombosis-free patency (59, 69 and 86% for low, middle and high tertiles; p = 0.02). Using Cox regression analysis, AVF thrombosis was predicted by baseline CD34+KDR+ cell counts (hazards ratio (HR) 0.963, 95% CI 0.928-1.000, p = 0.05) and tertiles (high vs. low, HR 3.266, 95% CI 1.380-7.728, p < 0.01). In multivariate analysis, only CD34+KDR+ cell tertiles, C-reactive protein and lesion length remained independent predictors for thrombosis. Conclusion: Our study demonstrated an independently reverse association between circulating EPCs and thrombosis of dialysis AVFs. Further studies are warranted to ascertain whether EPCs serve as a marker or a therapeutic target for AVF thrombosis.